Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published in the International Journal of Molecular Science ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments. The study published ...

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Palsonify, a once-daily oral SST2 agonist, offers a noninvasive alternative to monthly depot injections, long considered the standard medical therapy for acromegaly.

What began as a single clinic in Colorado has evolved into a well-regarded provider of hormone optimization and replacement care, now serving more than 10,000 patients.

A new Ohio University study offers a glimmer of hope in the fight against lung cancer. Monica Robins has that story and more ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya® (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...

Researchers from Ohio State University, led by Distinguished Professor John J. Coccyx and graduate student Arshad Ahmad from Heritage College of Osteopathic Medicine have discovered a potential new ...